17 recruiting, 14 not yet recruiting, 1 active not recruiting, 1 completed. 19 Phase 2, 9 Phase 1, 4 Phase 3, 2 Not applicable, 1 Phase 4.
Follow Biliary Tract Cancer (BTC): new trials by email Literature Review of Biliary Tract Cancer (BTC) trials Research Report on Biliary Tract Cancer (BTC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine - Biliary Tract Cancer (BTC) | Phase 3 | Not yet recruiting | UNICANCER | 990 | 2027-01-02 | 2026-08-04 |
| IKS04 Regimen in Advanced Solid Tumors That Express CA242 IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody - Colorectal Cancer, Gastro Esophageal Junctional Cancer | Phase 1 | Not yet recruiting | Iksuda Therapeutics Ltd. | 120 | 2026-11-01 | 2026-07-31 |
| Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors PD-1 and chemotherapy, cryoablation - Biliary Tract Cancer (BTC) | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-10-01 | 2026-07-24 |
| A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract Cancer Ivonescimab, GEMOX Regimen - Biliary Tract Cancer (BTC) | Phase 2 | Recruiting | Haitao Zhao, MD | 87 | 2026-10-01 | 2026-10-02 |
| A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer Sacituzumab Tirumotecan (SKB264), Pembrolizumab - Biliary Tract Cancer (BTC) | Phase 2 | Recruiting | Haitao Zhao, MD | 38 | 2026-10-01 | 2026-10-05 |
| Bile ctDNA Genomic Profiling and Concordance With Tumor Tissue in Biliary Tract Cancer Bile Sampling for ctDNA Analysis - Biliary Tract Cancer (BTC) | Not yet recruiting | CHA University | 100 | 2026-10-01 | 2026-10-13 | |
| Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer. QL1706 (Iparomlimab/Tuvonralimab), Lenvatinib, Cryoablation - Biliary Tract Cancer (BTC) | Phase 2 | Not yet recruiting | Fudan University | 180 | 2026-09-20 | 2026-09-21 |
| Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma Pemigatinb, PD-1 inhibitors, Chemotherapy - Biliary Tract Cancer (BTC) | Phase 2 | Recruiting | Haitao Zhao, MD | 154 | 2026-08-20 | 2026-08-26 |
| SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors SKL35501, SKL35502 - Selected Advanced Solid Tumors, Colorectal Cancer (CRC) | Phase 1 | Recruiting | SK Life Science, Inc. | 100 | 2026-08-19 | 2026-09-10 |
| YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies YMN-136 vaccine - Liver Cancer, Pancreatic Cancer | Phase 1 | Recruiting | West China Hospital | 9 | 2026-08-01 | 2026-08-13 |
| QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer Iparomlimab and Tuvonralimab (QL1706), Gemcitabine and Cisplatin Chemotherapy - Biliary Tract Cancer (BTC) | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 38 | 2026-07-20 | 2026-07-29 |
| A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCER No intervention - Biliary Tract Cancer (BTC) | Not yet recruiting | MedSIR | 244 | 2026-07-01 | 2026-04-07 | |
| Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers mFOLFOX regimen, Mitazalimab - Biliary Tract Cancer (BTC) | Phase 2 / Phase 3 | Not yet recruiting | UNICANCER | 160 | 2026-07-01 | 2026-02-27 |
| Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II Becotatug Vedotin, Pucotenlimab - Biliary Tract Cancer (BTC), EGFR-positive Advanced Biliary Tract Carcinoma | Phase 2 | Not yet recruiting | HuiKai Li | 30 | 2026-07-01 | 2026-06-16 |
| Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer Sintilimab + GC, SBRT 7Gy✖️5 QD - Biliary Tract Cancer (BTC) | Phase 2 | Not yet recruiting | Eastern Hepatobiliary Surgery Hospital | 123 | 2026-06-15 | 2026-06-10 |
| A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer Iparomlimab and Toripalimab, Bevacizumab, Gemcitabine (1000 mg/m2) - Biliary Tract Cancer (BTC) | Phase 4 | Recruiting | Xianglin Yuan | 32 | 2026-06-10 | 2026-09-15 |
| D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer D07001-Softgel Capsules, Placebo, Capecitabine - Biliary Tract Cancer (BTC) | Phase 3 | Recruiting | InnoPharmax Inc. | 240 | 2026-06-09 | 2026-07-30 |
| A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer Nanvuranlat, Physician's Best Choice - Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC) | Phase 3 | Recruiting | J-Pharma Co., Ltd. | 480 | 2026-05-11 | 2026-09-29 |
| HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer HAIC(GOLF), Bevacizumab, PD-1/PD-L1 inhibitor - Biliary Tract Cancer (BTC) | Not applicable | Recruiting | Peking University | 40 | 2026-03-31 | 2026-05-08 |
| TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA) | Not yet recruiting | Aarhus University Hospital | 300 | 2026-03-15 | 2026-03-06 |
Showing 20 of 35. Sign in to see all of them.
Biliary Tract Neoplasms (35) · Cholangiocarcinoma (7) · Colorectal Neoplasms (4) · Gallbladder Neoplasms (3) · Neoplasm Metastasis (3) · Stomach Neoplasms (3) · Endometrial Neoplasms (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Esophageal Neoplasms (1) · Klatskin Tumor (1) · Liver Neoplasms (1)
Biliary Tract Diseases (35) · Digestive System Diseases (35) · Digestive System Neoplasms (35) · Neoplasms by Site (35) · Neoplasms (33) · Neoplasms by Histologic Type (9) · Neoplasms, Glandular and Epithelial (9) · Adenocarcinoma (8) · Carcinoma (8) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Colonic Diseases (4) · Intestinal Diseases (4) · Intestinal Neoplasms (4) · Neoplastic Processes (4)
Gemcitabine (8) · Cisplatin (5) · Folfox protocol (4) · Oxaliplatin (4) · Bevacizumab (3) · Drug Therapy (3) · Immune Checkpoint Inhibitors (3) · Leucovorin (3) · Paclitaxel (3) · Capecitabine (2) · Cryosurgery (2) · Fluorouracil (2) · lenvatinib (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1)
Fudan University (3) · Haitao Zhao, MD (3) · UNICANCER (2) · Aarhus University Hospital (1) · Avenzo Therapeutics, Inc. (1) · CHA University (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chinese PLA General Hospital (1) · Eastern Hepatobiliary Surgery Hospital (1) · HuiKai Li (1) · I-Mab Biopharma US Limited (1) · Iksuda Therapeutics Ltd. (1) · Incyte Corporation (1) · InnoPharmax Inc. (1) · J-Pharma Co., Ltd. (1)
China (17) · United States (10) · Taiwan (3) · South Korea (2) · United Kingdom (2) · Belgium (1) · Denmark (1) · France (1)
Feng Shen (2) · Chia Jui Yen, MD., PhD (1) · Criss Cheng (1) · Eric K Rowinsky, MD (1) · Ghassan Abou-Alfa, MD (1) · Guruprasad P Aithal, MBBS, MD, PhD (1) · James O'Leary, MD (1) · Jia Fan, Professor (1) · Jian Zhou (1) · Julien Edeline, MD (1) · Jun Xue (1) · Karen-Lise Garm Spindler, Professor, MD, PhD (1) · Lance Leopold, MD (1) · Li-Tzong Chen, MD (1)
2017 (1), 2025 (1)